Moreover, it has been suggested that patients with Dravet syndrome and patients with SCN1A variants causing loss of function of the Na+ channel should avoid Na+ channel blocking anti-epileptic drugs. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.